RxDoctor Payments Data

Jasmine Adams, PA

Physician Assistant · Clarksville, TNNPI 1669011094

Payments from drug & device makers

$1,422in general payments, 2019–2025

Across 75 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$397
  • Novo Nordisk$379
  • Bayer$73
  • Alkermes, Inc.$71
  • Medtronic$68
  • Axsome Therapeutics, Inc.$57
  • plus $378 from 11 others

What the payments were for

  • Food & beverage$1,40799%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca20$397
Novo Nordisk20$379
Bayer4$73
Alkermes, Inc.4$71
Medtronic4$68
Axsome Therapeutics, Inc.2$57
Merck3$55
Lilly USA, LLC3$51
AbbVie2$51
GSK3$49
Exact Sciences3$48
Pfizer2$35
Dexcom, Inc.1$25
Ossur Americas, Inc.1$18
Indivior Inc.1$17
Amgen1$16
USWM, LLC1$12

How this compares

$1,422 in reported general payments places this provider in the 70th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$40,756
Medicare patients
195
Services billed
1,093

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$110,680
Tresiba Flextouch U-200Insulin Degludec15$20,538
MounjaroTirzepatide18$19,564
JardianceEmpagliflozin16$16,283
FarxigaDapagliflozin Propanediol15$11,990
EliquisApixaban19$11,564
SymbicortBudesonide/Formoterol Fumarate13$2,966
Novolog FlexpenInsulin Aspart13$2,144
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,071
Esomeprazole Magnesium29$1,688
Albuterol Sulfate HfaAlbuterol Sulfate74$1,176
Rosuvastatin Calcium66$1,081
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen41$1,063
Oxcarbazepine15$997
Atorvastatin Calcium119$953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$379$110,68077 claims
Lilly USA, LLCMounjaro$51$19,56418 claims
AstraZenecaFarxiga, Symbicort$397$14,95728 claims
PfizerEliquis$35$11,56419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Clarksville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →